GSK plc: Charging Into The Vaccine Race With High-Stakes 30-Valent Pneumococcal Launch Plan!

The results from the second quarter of 2025 for GlaxoSmithKline (GSK) reflect a balance of robust growth in specialty medicines and vaccines alongside some crucial challenges and areas for cautious monitoring. The company reported a 6% increase in group sales, with a notable boost from its specialty medicines division, which saw a 15% rise. Vaccine sales also performed well, growing by 9%. This growth led to a 12% increase in core operating profit and a 15% rise in core earnings per share, reaching 46.5p.